U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements
  1. Search for FDA Guidance Documents


CPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements March 1995

Docket Number:
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health
Office of Regulatory Affairs


It is our concept of section 502(f)(l) *of the Federal Food, Drug, and Cosmetic Act (the Act)* and the pertinent regulations that an ineffective device cannot be brought into compliance with that section. *21 CFR* 80l.5 defines "adequate directions for use" as meaning directions under which the layman could use a device for the purposes for which it is intended. This wording implies that the directions for use must be such as to enable the user to employ the article successfully for the intended purpose. Obviously, it is not possible to prepare directions that would enable the layman to use a device which is not effective for any medical purpose.


*Ineffective devices are misbranded within the meaning of Section 502(f)(l) of the act. Such devices cannot meet the criteria for "adequate directions for use" for layman use (21 CFR 80l.5) or the exemption for use by licensed practitioners under 21 CFR 80l.l09. Prior to preparing a recommendation for legal action, the district should assure that the situation meets the conditions for considering regulatory action stated in Compliance Policy Guide 7150.10, Health Fraud - Factors in Considering Regulatory Action.*

*(Please Note - The Health Fraud definition includes the "... promotion, advertisement, distribution or sale of articles, intended for human or animal use ...").*

*Material between asterisks is new or revised*

Issued: 4/26/76

Revised: 10/1/80, 11/21/88, 3/95

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top